Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600
-- Product is targeting rare pediatric endocrinology condition ---- Potential for NDA submission in Q2 2024 -- DEER PARK, Ill., March 15, 2023 -- Eton Pharmaceuticals , an innovative... | March 15, 2023